Mukka Proteins Announces 16th AGM on Sep 10, 2026; Releases FY26 Annual Report
Mukka Proteins will hold its 16th AGM on September 10, 2026. The company reported FY26 consolidated revenue of ₹1,449.5 crore (up 44.0%) and PAT of ₹57.1 crore (up 18.7%). They aim for ₹3,000 crore revenue by FY30, supported by diversification and international expansion.
The announcement of the AGM and the release of the annual report with financial performance are routine yet important for investors. The financial growth and future targets suggest a positive but not disruptive impact.
The announcement details the upcoming AGM and presents strong financial results for FY26, along with clear future growth ambitions, indicating a positive outlook.
Mukka Proteins Limited has announced its 16th Annual General Meeting (AGM) scheduled for Thursday, September 10, 2026, at 3:00 PM IST, to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company has also released its Annual Report for the financial year 2025-26.
The Annual Report and the Notice of the 16th AGM are available on the company's website and have been emailed to eligible members. The company is providing an e-voting facility for its members. The cut-off date to determine eligibility for voting is Thursday, September 3, 2026. The remote e-voting period will commence on Monday, September 7, 2026, at 9:00 AM IST and conclude on Wednesday, September 9, 2026, at 5:00 PM IST. Members attending the AGM via VC/OAVM who did not cast their vote remotely will be able to vote during the meeting.
The company reported a strong financial performance for FY26, with revenue from operations increasing by 44.0% to ₹1,449.5 crore and Profit After Tax (PAT) growing by 18.7% to ₹57.1 crore on a consolidated basis. The company also highlighted its strategic progress, including expansion in waste management, acquisition of Ento Proteins, and strengthening its international footprint with a facility in Oman and incorporation of Lanka Bio Proteins Private Limited in Sri Lanka. The company aims to exceed ₹3,000 crore in revenue by FY30.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.